RxDoctor Payments DataLook up a doctor →

Chantil Jeffreys

Family · Germantown, TNNPI 1942285465

Payments from drug & device makers

$194,591in general payments, 2019–2025

Across 988 payments — averaging $196.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$39K
  • Intercept Pharmaceuticals, Inc.$33K
  • Phathom Pharmaceuticals, Inc.$31K
  • Ipsen Biopharmaceuticals, Inc$16K
  • Novo Nordisk$13K
  • Madrigal Pharmaceuticals$13K
  • plus $49K from 31 others
$1,492in research payments, 2019–2025

Across 11 payments — averaging $135.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$1K

What the payments were for

  • Consulting fees$13,6607%
  • Speaking & faculty fees$108,35256%
  • Travel & lodging$50,04426%
  • Food & beverage$22,18011%
  • Education$3540%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$194,591 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$82,522
Medicare patients
324
Services billed
1,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase47$148,711
XifaxanRifaximin16$38,070
LinzessLinaclotide28$31,893
ZenpepLipase/Protease/Amylase12$26,236
ViberziEluxadoline19$24,508
Mesalamine13$6,077
ClenpiqSod Picosulf/Mag Ox/Citric Ac24$3,918
Promethazine Hcl27$3,583
Balsalazide Disodium12$2,657
Esomeprazole Magnesium41$2,098
Omeprazole70$1,540
Sucralfate41$1,470
Pantoprazole Sodium83$1,343
Dicyclomine Hcl55$1,273
Ondansetron OdtOndansetron29$809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Viberzi$3,284$205,11294 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$5,493$38,07016 claims
Aimmune Therapeutics, Inc.Zenpep$249$26,23612 claims
Ferring Pharmaceuticals Inc.Clenpiq$62$3,91824 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →